Magdalena Kozielska
Overview
Explore the profile of Magdalena Kozielska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kozielska M, Weissing F
PLoS Comput Biol
. 2024 Jan;
20(1):e1011840.
PMID: 38289971
Learning from past experience is an important adaptation and theoretical models may help to understand its evolution. Many of the existing models study simple phenotypes and do not consider the...
2.
Kalita A, Marois E, Kozielska M, Weissing F, Jaouen E, Mockel M, et al.
Nature
. 2023 Sep;
623(7985):175-182.
PMID: 37769784
The Anopheles mosquito is one of thousands of species in which sex differences play a central part in their biology, as only females need a blood meal to produce eggs....
3.
Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy
Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton H, Grimwood S, et al.
Pharm Res
. 2016 Mar;
33(5):1305-6.
PMID: 26964545
No abstract available.
4.
Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton H, Grimwood S, et al.
Pharm Res
. 2016 Jan;
33(4):1003-17.
PMID: 26718955
Objectives: To assess the ability of a previously developed hybrid physiology-based pharmacokinetic-pharmacodynamic (PBPKPD) model in rats to predict the dopamine D2 receptor occupancy (D2RO) in human striatum following administration of...
5.
Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton H, Grimwood S, et al.
Pharm Res
. 2014 May;
31(10):2605-17.
PMID: 24792824
Objectives: Dopamine D2 receptor occupancy (D2RO) is the major determinant of efficacy and safety in schizophrenia drug therapy. Excessive D2RO (>80%) is known to cause catalepsy (CAT) in rats and...
6.
Pilla Reddy V, Kozielska M, Johnson M, Mafirakureva N, Vermeulen A, Liu J, et al.
J Clin Psychopharmacol
. 2013 Oct;
33(6):731-9.
PMID: 24113674
The aim of this study was to develop a pharmacokinetic-pharmacodynamic (PKPD) model that quantifies the efficacy of haloperidol, accounting for the placebo effect, the variability in exposure-response, and the dropouts....
7.
Pilla Reddy V, Kozielska M, Suleiman A, Johnson M, Vermeulen A, Liu J, et al.
Schizophr Res
. 2013 Mar;
146(1-3):153-61.
PMID: 23473811
Background And Objectives: The superiority of atypical antipsychotics (also known as second-generation antipsychotics (SGAs)) over typical antipsychotics (first generation antipsychotics (FGAs)) for negative symptom control in schizophrenic patients is widely...
8.
Pilla Reddy V, Kozielska M, Suleiman A, Johnson M, Vermeulen A, Liu J, et al.
Schizophr Res
. 2013 Mar;
146(1-3):144-52.
PMID: 23473810
Background: To develop a pharmacokinetic-pharmacodynamic (PK-PD) model using individual-level data of Positive and Negative Syndrome Scale (PANSS) total score to characterize the antipsychotic drug effect taking into account the placebo...
9.
Kozielska M, Pilla Reddy V, Johnson M, De Ridder F, Vermeulen A, Liu J, et al.
Schizophr Res
. 2013 Feb;
146(1-3):53-8.
PMID: 23434198
Lack of hard clinical endpoints is an essential problem in schizophrenia research. Disease state and treatment outcomes are measured using rating scales, e.g. Positive and Negative Syndrome Scale (PANSS). However,...
10.
Pilla Reddy V, Kozielska M, de Greef R, Vermeulen A, Proost J
J Pharmacokinet Pharmacodyn
. 2013 Jan;
40(3):377-88.
PMID: 23315146
High and variable placebo effect (PE) within and among clinical trials can substantially affect conclusions about the efficacy of new drugs in the treatment of schizophrenia and other neuropsychiatric disorders....